These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34540198)

  • 1. Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions.
    Chavez JC; Yassine F; Sandoval-Sus J; Kharfan-Dabaja MA
    Int J Hematol Oncol; 2021 Jun; 10(2):IJH33. PubMed ID: 34540198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.
    Onea AS; Jazirehi AR
    Am J Cancer Res; 2016; 6(2):403-24. PubMed ID: 27186412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.
    Cao Y; Lu W; Sun R; Jin X; Cheng L; He X; Wang L; Yuan T; Lyu C; Zhao M
    Front Oncol; 2019; 9():767. PubMed ID: 31482064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Yin Z; Zhang Y; Wang X
    Biomark Res; 2021 Jul; 9(1):58. PubMed ID: 34256851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm.
    Hill L; Lulla P; Heslop HE
    Adv Cell Gene Ther; 2019 Jul; 2(3):. PubMed ID: 31777773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
    Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
    Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
    Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.
    Makita S; Imaizumi K; Kurosawa S; Tobinai K
    Drugs Context; 2019; 8():212567. PubMed ID: 30815024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
    Kanwal B
    Cureus; 2021 Jul; 13(7):e16307. PubMed ID: 34277304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Makita S; Yoshimura K; Tobinai K
    Cancer Sci; 2017 Jun; 108(6):1109-1118. PubMed ID: 28301076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
    Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
    Front Immunol; 2021; 12():681984. PubMed ID: 34248965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
    Zhang Y; Li J; Lou X; Chen X; Yu Z; Kang L; Chen J; Zhou J; Zong X; Yang Z; Li M; Xu N; Jia S; Geng H; Chen G; Dai H; Tang X; Yu L; Wu D; Li C
    Front Oncol; 2021; 11():664421. PubMed ID: 34113569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
    Du J; Zhang Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.
    Zhu H; Deng H; Mu J; Lyu C; Jiang Y; Deng Q
    Onco Targets Ther; 2021; 14():4023-4037. PubMed ID: 34239307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.